EXHIBIT A JOINT FILING AGREEMENT <*$p$*>Notwithstanding Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to delay the joint filing on behalf of each of them of a statement on Schedule 13G (excluding any amendments thereto) with respect to the Common Stock of Spring Bank Pharmaceuticals, Inc. and further agree that this agreement not be included as an exhibit to such filing until one year after the initial filing date.<*$p$*> <*$p$*>No party to this agreement authorizes any other party to file on its behalf any amendments to such statement without the express written consent of legal counsel, such consent to be provided no earlier than six months following the initial filing date.<*$p$*> Each party to this agreement agrees that this joint filing agreement may be signed in counterparts. <*$p$*>This Agreement shall not be considered fully executed until all parties have provided notarized signatures, to be completed no later than December 31st, 2021.<*$p$*> UBS ONCOLOGY IMPACT FUND L.P. ONCOLOGY IMPACT FUND (CAYMAN) MANAGEMENT L.P. By: Oncology Impact Fund (Cayman) Management L.P, By: MPM Oncology Impact Management LP, its General Partner its General Partner By: MPM Oncology Impact Management LP, By: MPM Oncology Impact Management GP LLC, its General Partner its General Partner By: MPM Oncology Impact Management GP LLC, By: /s/ Ansbert Gadicke its General Partner Name: Ansbert Gadicke Title: Managing Member By: /s/ Ansbert Gadicke Name: Ansbert Gadicke Title: Managing Member MPM ONCOLOGY IMPACT MANAGEMENT LP MPM ONCOLOGY IMPACT MANAGEMENT GP LLC By: MPM Oncology Impact Management GP LLC, By: /s/ Ansbert Gadicke its General Partner Name: Ansbert Gadicke Title: Managing Member By: /s/ Ansbert Gadicke Name: Ansbert Gadicke Title: Managing Member